pharmaphorum

AUGUST 5, 2021

In a provisional judgment, the CMA has concluded that Pfizer and Flynn abused a dominant position to overcharge the NHS for phenytoin sodium capsules, causing NHS spending on the drug to balloon from around £2 million a year in 2012 to £50 million the following year.

Drug Pricing 52

Drug Pricing 52

pharmaphorum

NOVEMBER 27, 2020

Vertex introduced Kalydeco in 2012, and has since followed up with launches of two-drug combinations Orkambi (lumacaftor/ivacaftor) and Symkevi – known as Symdeko in the US – in 2015 and 2018, respectively. Together these drugs cover the CFTR mutations seen in around half of all CF patients.

Labelling 134

Labelling Drug Pricing 134

Putting Patients First Blog

SEPTEMBER 7, 2023

Cardiac screening The use of echocardiogram and cardiac MRI in Duchenne increased across most age groups when comparing the time periods 2007-2012, 2013-2017, and 2018-2022 with some age groups having statistical significance. The average age at loss of ambulation for registrants who never used corticosteroids was 10.5

Drug Pricing 111

Drug Pricing 111

pharmaphorum

DECEMBER 7, 2022

Having recently assessed the relationship between drug price and prevalence of non-oncology rare diseases, CRA’s Life Sciences Practice team explores in greater depth the situation for these orphan drugs in France in this final article of a three-part series. Influence of ATUc programme on drug pricing.

Drug Pricing 105

Drug Pricing Drug Development 105

pharmaphorum

OCTOBER 26, 2022

The two drugmakers were fined in July, after the CMA upheld a preliminary judgment that Pfizer and Flynn had abused a dominant position in phenytoin sodium capsules, causing NHS spending on the drug to swell from around £2 million a year in 2012 to £50 million the following year.

Drug Pricing 105

Drug Pricing 105

pharmaphorum

JANUARY 28, 2021

At the same time, the average cost of insulin for patients per year almost doubled from $2,864 to $5,705 between 2012 and 2016. Currently, more than seven million patients rely on insulin, and that number is growing each year. Americans pay ten times as much for insulin as Canadian patients do.

Biosimilars 119

Biosimilars Insurance Coverage and Processing Drug Pricing Diabetes 119

FDA Law Blog: Biosimilars

APRIL 16, 2024

Under the Medicaid Drug Rebate statute, a pharmaceutical manufacturer whose drug prices increase faster than the rate of inflation must pay additional per-unit rebates to the program. Vanda Pharmaceuticals, Inc. Centers for Medicare and Medicaid Servs., 23-1457 (4th Cir.

Dosage 59

Dosage Drug Pricing Pharmaceutical Manufacturing 59

Safe Biologics

MAY 10, 2024

View ASBM’s educational fact sheet “Interchangeability: US vs EU” here. Biden’s SOTU: 500 Drugs To Be Subject to Medicare Drug Price Controls On March 7th, President Biden gave his State of the Union address to Congress, wherein he laid out upcoming policy priorities for a potential second term.

Biosimilars 130

Biosimilars Drug Pricing Documentation Labelling 130

pharmaphorum

AUGUST 5, 2022

In addition to the climate provisions, however, the bill has a significant effect on prescription drug prices, and according to reports neither Manchin nor Sinema is objecting to these provisions, which are similar but not identical to the ones in the Build Back Better plan which previously passed in the House of Representatives.

Drug Pricing 111

Drug Pricing Pharmaceutical Companies Pharmaceutical Companies Vaccines 111